secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001104659-23-057825
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q1 net income $34.9M ($0.51 EPS); GSK royalties $60.3M
---------------------------------------------------------------

- Net income $34.9M ($0.51 basic EPS) vs $15.8M ($0.23) YoY.
- GSK royalty revenue $60.3M, down from $93.5M YoY due to TRELEGY royalty sale in July 2022.
- Net product sales & license revenue $19.5M ($9M GIAPREZA, $2.5M XERAVA, $8M milestone from China XERAVA approval).
- Repurchased $40.3M of common stock (3.4M shares); paid off $96.2M of 2023 convertible notes.
- FDA advisory committee unanimously voted 12-0 for sulbactam-durlobactam; PDUFA target date May 29, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923057825/0001104659-23-057825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923057825/tm2315160d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-057825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer